Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare cancer registry aims to unlock treatment secrets

NCT ID NCT05430971

Knowledge-focused Sponsor: Immune Oncology Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on how the disease presents, how it is treated, and what happens to patients over time. The goal is to learn from real-world data to improve future treatment recommendations. No experimental therapy is given; participants simply allow their medical data to be used for research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with BPDCN diagnosed since 01.01.2010

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites in 15 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group

    RECRUITING

    Chelmsford, Essex, CM1 7ET, United Kingdom

  • Children's Hospital of Eastern Ontario, University of Ottawa

    RECRUITING

    Ottawa, Ontario, K1H 8L1, Canada

  • China Medical University Children's Hospital

    RECRUITING

    Taichung, 40447, Taiwan

  • Cyprus Society of Haematology

    RECRUITING

    Nicosia, 2019, Cyprus

  • Department of Biomedicine and Prevention, University of Rome Tor Vergata

    RECRUITING

    Roma, 00133, Italy

  • Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences

    RECRUITING

    New Delhi, 110029, India

  • Department of hematology, Kuwait Cancer Control Center

    RECRUITING

    Kuwait City, 42262, Kuwait

  • Fundeni Clinical Institute, Department of Acute Leukemia

    RECRUITING

    Bucharest, 022328, Romania

  • Hematology Center named after prof. R. Yeolyan

    RECRUITING

    Yerevan, 0014, Armenia

  • Istanbul University, Oncology Institute

    RECRUITING

    Istanbul, 34093, Turkey (Türkiye)

  • King Hussein Cancer Center (KHCC)

    RECRUITING

    Amman, 11941, Jordan

  • M. Iashvili Children's Central Hospital

    RECRUITING

    Tbilisi, 0159, Georgia

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Oncology Center, Mansoura University Faculty of Medicine

    RECRUITING

    Al Mansurah, 7650030, Egypt

  • Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad

    RECRUITING

    Baghdad, 61023, Iraq

  • Seattle Children's Cancer and Blood Disorders Center

    RECRUITING

    Seattle, Washington, 98145, United States

  • Sylvester Comprehensive Cancer Center, University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • Turkish Pediatric Cancer Registry

    RECRUITING

    Ankara, 06690, Turkey (Türkiye)

  • United Lincolnshire Teaching Hospital NHS Trust

    RECRUITING

    Lincoln, Lincolnshire, LN2 5QY, United Kingdom

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 1N4, Canada

  • University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit

    RECRUITING

    Istanbul, 34766, Turkey (Türkiye)

  • University of Perugia - Azienda Ospedaliera Perugia

    RECRUITING

    Perugia, 06129, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.